Skip to main content

Table 3 Mean and SEM values for the monitored diabetes-related parameters Hb1Ac, glucose and insulin in blood from the NHPs at baseline and during treatment with the omega-3 rich phospholipids. Dose levels of administered phospholipids, EPA, DHA and choline are given at the end of the table

From: Effects of a purified krill oil phospholipid rich in long-chain omega-3 fatty acids on cardiovascular disease risk factors in non-human primates with naturally occurring diabetes type-2 and dyslipidemia

Parameter

Group

Value

Baseline

Week after start of treatment

2

4

6

8

10

12

Hb1Ac (%)

Control

Mean

9.07

8.60

9.00

9.00

9.37

9.43

9.80

SEM

2.31

2.05

2.35

2.40

2.56

2.69

2.87

Treated

Mean

6.63

6.53

6.50

6.40

6.50

6.40

6.67

SEM

1.43

1.64

1.46

1.37

1.23

1.48

1.49

Glucose (mg(dL)

Control

Mean

195

197

196

182

177

181

203

SEM

64.1

71.8

62.0

61.4

65.8

64.5

71.9

Treated

Mean

148

135

157

127

158

119

141

SEM

41.2

31.7

38.3

35.5

30.0

20.0

32.3

Insulin (mIU/mL)

Control

Mean

33.1

26.3

21.9

46.2

20.9

21.8

28.1

SEM

5.27

5.32

4.86

21.28

5.51

5.61

10.5

Treated

Mean

66.7

112

104

91.6

115

74.2

96.7

SEM

29.6

52.1

44.3

40.7

60.5

29.0

54.1

Dose (mg phospholipids/kg bw/day)

50

150

450

Dose (mg [EPA/DHA]/kg bw/day)

9,35/5,48

28,1/16,4

84.2/49.3

Dose (mg choline/kg bw/day)

5,83

17,5

52,5